Cash from Investing (Quarterly) Chart

View Cash from Investing (Quarterly) for COCP.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Investing (Quarterly) Chart
Start Trial

Historical Cash from Investing (Quarterly) Data

View and export this data back to 2008. Start Trial.
Date Value
June 30, 2026 0.00
March 31, 2026 0.00
December 31, 2025 0.00
September 30, 2025 -0.0126M
June 30, 2025 0.00
March 31, 2025 0.00
December 31, 2024 0.0002M
September 30, 2024 0.0005M
June 30, 2024 0.0001M
March 31, 2024 -0.008M
December 31, 2023 -0.057M
September 30, 2023 -0.0015M
June 30, 2023 -0.0156M
March 31, 2023 -0.045M
December 31, 2022 -0.0134M
September 30, 2022 -0.0623M
June 30, 2022 0.00
March 31, 2022 0.00
December 31, 2021 -0.0066M
September 30, 2021 -0.0038M
June 30, 2021 -0.0153M
March 31, 2021 -0.025M
December 31, 2020 -0.0178M
September 30, 2020 -0.0286M
June 30, 2020 -0.1116M
Date Value
March 31, 2020 -0.093M
December 31, 2019 -0.0017M
September 30, 2019 -0.1142M
June 30, 2019 -0.0041M
March 31, 2019 -0.025M
December 31, 2018 -0.0627M
September 30, 2018 0.0235M
June 30, 2018 -0.0244M
March 31, 2018 1.395M
December 31, 2017 0.0157M
September 30, 2017 -0.0011M
June 30, 2017 -0.0215M
March 31, 2017 -0.033M
December 31, 2016 0.0338M
September 30, 2016 0.0219M
June 30, 2016 -0.0539M
March 31, 2016 0.001M
December 31, 2015 -0.0957M
September 30, 2015 -0.1714M
June 30, 2015 0.0048M
March 31, 2015 0.014M
December 31, 2014 2.470M
September 30, 2014 -0.0205M
June 30, 2014 2.805M
March 31, 2014 0.576M

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
CNBX Pharmaceuticals, Inc. 0.00
GB Sciences, Inc. --
Arvinas, Inc. 54.90M
Fulcrum Therapeutics, Inc. 13.78M
Definium Therapeutics, Inc. -315.46M